{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-365132","form_type":"8-K","ticker":"PBLS","cik":"0001657677","company_name":"Parabilis Medicines, Inc.","filed_at":"2026-08-25T20:10:15+00:00","discovered_at":"2026-08-25T20:11:06.833367+00:00","generated_at":"2026-08-25T20:11:27.694994+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Parabilis Medicines appoints Craig Tendler to board as independent Class II director","bullets":["Board expanded to nine; Craig Tendler, M.D., appointed Class II director on Aug 22, 2026, term to 2028.","Receives stock option for 20,294 shares at $39.36/share, vesting monthly over 3 years.","Annual retainer of $40,000 for board plus $7,500 for Science & Technology Committee service.","Tendler brings 30+ years oncology development incl. two decades at J&J; joins Science & Technology Committee."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-365132","json":"https://secwatch.observer/filing/0001193125-26-365132.json","markdown":"https://secwatch.observer/filing/0001193125-26-365132.md","text":"https://secwatch.observer/filing/0001193125-26-365132.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1657677/000119312526365132/0001193125-26-365132-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1657677/000119312526365132/ck0001657677-20260822.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-25T20:11:27.694994+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}